InfectionEC-MOTIONNCT02917486
EC-MOTION : ExtraCorporeal Membrane Oxygenation and Therapeutic Drug Monitoring of Drugs of infectION
An observational study of Infection, run by Rennes University Hospital at 1 site in France.
Trial summary
The objective of the study is to investigate the exposure difference between antibiotic studied patients in intensive care with Extracorporeal Membrane Oxygenation and patients without Extracorporeal Membrane Oxygenation. The exhibition is evaluated by population pharmacokinetic modeling. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Infection
- What is being tested?
- blood sample
- How many people
- 44 participants
- Where
- 1 siteFrance
- Study dates
- Jan 2016to Jul 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients in intensive care treated with ECMO or without ECMO
Who may be able to join
- Age over 18 years
- Hospitalisation in intensive care
- Treatment with ECMO or without ECMO
- Introducing sepsis treated with an anti-infective molecule studied (piperacillin) for less than 48 hours
- With an arterial catheter
- Patient Information or their next of kin according to the patients status.
Who cannot join
- Pregnancy
- Major person under legal protection (backup justice, trusteeship, quardianship), person deprived of liberty
Trial locations and contacts
1 site in 1 country.
About this study
The objective of the study is to investigate the exposure difference between antibiotic studied patients in intensive care with Extracorporeal Membrane Oxygenation and patients without Extracorporeal Membrane Oxygenation.
The exhibition is evaluated by population pharmacokinetic modeling.
- Conditions
- Infection
- Being tested
- blood sample
- Keywords
- ExtraCorporeal Membrane Oxygenation, patient in intensive care, pharmacokinetic modeling
- Medical subject headings
- Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
blood sampleOther
| Study group | Role | What they receive |
|---|---|---|
| ECMO piperacillin | patients in intensive care treated with ECMO with antiinfective therapy : piperacillin Receives: Other: blood sample | |
| without ECMO piperacillin | patients in intensive care without ECMO with antiinfective therapy : piperacillin Receives: Other: blood sample |
What is being measured
The primary outcome is the main question the study is designed to answer.
Measure exposure to piperacillin
evaluated by population pharmacokinetic modeling and is defined by the time during which the antibiotic concentration is greater than 4 times the critical concentration of the germ to treat
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Sep 2016 (estimated)
- Study startJan 2016
- Primary completionJan 2019
- Study completionJul 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for InfectionStudies of the same condition, open and under way.
- More trials run by Rennes University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 44 participants (actual)
Sponsor and investigators
- Lead sponsor
- Rennes University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Pierre Fillatre, Principal investigator, Rennes University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02917486
- Sponsor's protocol ID
- 35RC15_8901
- Acronym
- EC-MOTION
- Status last verified
- Jun 2026
- First submitted
- 5 Sep 2016
- Last updated
- 12 Jun 2026
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- EC-MOTION : ExtraCorporeal Membrane Oxygenation and Therapeutic Drug Monitoring of Drugs of infectION
- ClinicalTrials.gov ID
- NCT02917486
- Acronym / sponsor ID
- EC-MOTION / 35RC15_8901
- Conditions
- Infection
- Keywords
- ExtraCorporeal Membrane Oxygenation, patient in intensive care, pharmacokinetic modeling
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 44 participants (actual)
- Lead sponsor
- Rennes University HospitalUniversity, hospital or other
- Study start
- Jan 2016 (actual)
- Primary completion
- Jan 2019 (actual)
- Study completion
- Jul 2019 (actual)
- First posted
- 28 Sep 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of the study is to investigate the exposure difference between antibiotic studied patients in intensive care with Extracorporeal Membrane Oxygenation and patients without Extracorporeal Membrane Oxygenation.
The exhibition is evaluated by population pharmacokinetic modeling.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| ECMO piperacillin | – | Other: blood samplepatients in intensive care treated with ECMO with antiinfective therapy : piperacillin |
| without ECMO piperacillin | – | Other: blood samplepatients in intensive care without ECMO with antiinfective therapy : piperacillin |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients in intensive care treated with ECMO or without ECMO
Key inclusion criteria (6 listed)
- Age over 18 years
- Hospitalisation in intensive care
- Treatment with ECMO or without ECMO
- Introducing sepsis treated with an anti-infective molecule studied (piperacillin) for less than 48 hours
- With an arterial catheter
Key exclusion criteria (2 listed)
- Pregnancy
- Major person under legal protection (backup justice, trusteeship, quardianship), person deprived of liberty
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| blood sample | Other | ECMO piperacillin, without ECMO piperacillin |
Primary outcome
Measure exposure to piperacillin
Time frame: Day 1
evaluated by population pharmacokinetic modeling and is defined by the time during which the antibiotic concentration is greater than 4 times the critical concentration of the germ to treat
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jun 2026.
Related trials for Infection
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
RecruitingObservational study
Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
Hepatitis D
RecruitingObservational study
VIRal Pulmonary Infections in Older AGE
Viral Pulmonary Infections
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pierre Fillatre principal investigator
Rennes University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Infection, run by Rennes University Hospital at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Measure exposure to piperacillin (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2026.